| __timestamp | Agios Pharmaceuticals, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 159205000 |
| Thursday, January 1, 2015 | 141827000 | 174172000 |
| Friday, January 1, 2016 | 220163000 | 150976000 |
| Sunday, January 1, 2017 | 292681000 | 149380000 |
| Monday, January 1, 2018 | 1397000 | 187681000 |
| Tuesday, January 1, 2019 | 1317000 | 190434000 |
| Wednesday, January 1, 2020 | 2805000 | 206506000 |
| Friday, January 1, 2021 | 18777000 | 238029000 |
| Saturday, January 1, 2022 | 1704000 | 250127000 |
| Sunday, January 1, 2023 | 9504000 | 293274000 |
| Monday, January 1, 2024 | 4165000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, understanding cost dynamics is crucial. From 2014 to 2023, Agios Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue. Agios experienced a dramatic 97% drop from its peak in 2017, reflecting strategic shifts or operational efficiencies. In contrast, Amphastar's costs steadily rose, peaking in 2023 with a 46% increase from 2014, possibly indicating expansion or increased production. This divergence highlights the varied strategies companies employ to navigate the pharmaceutical market. While Agios may be focusing on cost-cutting or innovation, Amphastar's rising costs could suggest scaling operations or increased market demand. These insights provide a window into the strategic decisions shaping the future of these companies.
Cost Insights: Breaking Down Eli Lilly and Company and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses
ACADIA Pharmaceuticals Inc. vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Agios Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.